2026 ETA guideline on interference in immunoassay measurements used in assessment of thyroid function
Recommendations
As issued by the authors
In discordant thyroid function, exclude assay interference before diagnosing rare inherited (resistance to thyroid hormone) or tumoural conditions (TSHoma)
Liaison between clinician and clinical biochemistry teams is essential when investigating assay interference; further testing depends on clinical picture, initial biochemistry and local expertise
In a subset of cases, access to a regional centre for clinical assessment with specialised laboratory testing (biochemical, +/- genetic) may be required
When interference is identified, clear communication with the patient (ideally with reliable, accessible patient literature) and documentation to their physician are necessary
Professionals must stay updated on advances in testing and be alert for evolving assay interferences
Original publication
Composed by AI from the published abstract and checked against it. How Briefs are made →